Fundamental Data for REGN

REGENERON(NSDQ:REGN)

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron''s platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

# Employees: 919

Address: 777 Old Saw Mill River Road,Tarrytown,NY,USA

Phone: 914-347-7000

Fax: 914-347-2113

Website: www.regn.com

Email: invest@regeneron.com.

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

George D. Yancopoulos M.D. (Exec. V.P.; Chief Scint. Off.; Dir.)

Douglas S. McCorkle (V.P.; Contrl.; Asst. Treas.)

Roy P. Vagelos M.D. (Chmn.)

Leonard S. Schleifer M.D. (Presi.; C.E.O.; Dir.)

Murray A. Goldberg (Sr. V.P. Fin. & Admn.; C.F.O.; Treas.; Asst. Sec.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/25/2010

Mean EPS (Next Qtr): ($0.33)

Mean EPS (Year): ($0.80)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 11

Shares Performance

Period	REGN	Compare to S&P
YTD	0.54 %	-16.79 %
4 Weeks	4.95 %	3.81 %
12 Weeks	-17.33 %	-22.06 %

Shares Information

Analyst Coverage: Y

Avg Volume: 822755

Shares Outstanding: 80M

Market Cap: $1.49B

52 Week High: $23.11

52 Week Low: $12.05

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 REGN split by factor of 0.060

Earnings Performance

EPS Growth in Last Quarter: 94.74 %

EPS Growth in Last Year: 96.30 %

Sales Growth in Last Quarter: 30.46 %

Sales Growth in Last Quarter: 79.09 %

Financials

Qtr Book Value: $3.50

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 4.390